1866-LB: A Phase 2 Study of Mazdutide 9 mg in Chinese Adults with BMI of 30 kg/m2 or more

安慰剂 医学 内科学 减肥 肥胖 临床终点 尿酸 体质指数 胃肠病学 随机化 随机对照试验 病理 替代医学
作者
HONGWEI JIANG,Linong Ji,YAWEI ZHANG,Zhifeng Cheng,SHUGUANG PANG,XIAOLI LI,WEI QIU,QINGYANG MA,ZIHAN LIU,YANQI WANG,HUAN DENG,LEI QIAN
出处
期刊:Diabetes [American Diabetes Association]
卷期号:73 (Supplement_1) 被引量:6
标识
DOI:10.2337/db24-1866-lb
摘要

Introduction & Objective: To evaluate the efficacy and safety of 9 mg mazdutide, a once-weekly GLP-1 and glucagon receptor dual agonist, in Chinese participants with obesity. Methods: In a randomized, double-blind, placebo-controlled phase 2 trial (NCT04904913), 80 Chinese adults with a BMI of 30 kg/m2 or more (mean baseline body weight: 96.9 kg; mean baseline BMI: 34.3 kg/m2) were randomized to receive once-weekly, subcutaneous mazdutide 9 mg (n=60) or placebo (n=20) for 24 weeks. Subsequently, participants voluntarily chose to participate in an extended 24-week double-blind treatment period. The primary endpoint was the percentage change in weight from baseline at week 24. Results: At week 24, mean percentage change in weight from baseline were −13.3% (SE 0.8) with mazdutide 9 mg and 2.1% (1.5) with placebo (estimated treatment difference: −15.4% [95%CI: −18.8, −12.0], P <0.0001); 81.7%, 65.0% and 31.7% of participants with mazdutide achieved weight reduction of 5% or more, 10% or more, and 15% or more, respectively, while no participant with placebo achieved weight reduction of 5% or more. Furthermore, compared with placebo, greater improvements were observed with mazdutide at week 24 in multiple cardiometabolic risk factors, most notably in triglycerides (−43.5% with mazdutide, −1.7% with placebo), alanine aminotransferase (−32.8%, 12.7%) and serum uric acid (−102.2 µmol/L, −16.1 µmol/L). In participants with baseline liver fat content (as measured by MRI-PDFF) of 5% or more, the liver fat content was reduced by 73.3% after 24-week treatment of mazdutide. Mazdutide 9 mg was well tolerated, with no adverse event leading to treatment discontinuation reported. The most frequently reported adverse events were gastrointestinal, and most were mild to moderate in severity. Conclusion: In Chinese adults with a BMI of 30 kg/m2 or more, mazdutide 9 mg showed robust body weight reduction and prominent hepatic benefits. Disclosure H. Jiang: None. L. Ji: None. Y. Zhang: None. Z. Cheng: None. S. Pang: None. X. Li: None. W. Qiu: None. Q. Ma: Employee; Innovent Biologics (Suzhou) Co., Ltd. Z. Liu: Employee; Innovent Biologics. Y. Wang: Employee; Innoventbio. H. Deng: Employee; Innovent. L. Qian: Employee; Innoventbio.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
JamesPei的应助被地道的反差萌采纳,获得80
刚刚
王文艺发布了新的文献求助10
刚刚
怕黑的尔安完成签到,获得积分10
1秒前
WangC发布了新的文献求助10
1秒前
lll发布了新的文献求助10
1秒前
周如鑫完成签到,获得积分10
2秒前
南风完成签到,获得积分10
2秒前
2秒前
研友_VZG7GZ的应助被轻飏采纳,获得10
3秒前
木9完成签到 ,获得积分20
3秒前
Owen的应助被嘿嘿采纳,获得10
3秒前
传奇3的应助被lykkk采纳,获得10
3秒前
虫子完成签到,获得积分10
3秒前
ptcl完成签到,获得积分10
4秒前
plz94完成签到 ,获得积分10
4秒前
4秒前
4秒前
xxj发布了新的文献求助10
4秒前
五灵王的应助被薛定谔的猫采纳,获得10
4秒前
5秒前
拳头完成签到,获得积分10
5秒前
5秒前
5秒前
6秒前
6秒前
星辰大海的应助被Rae采纳,获得10
7秒前
赘婿的应助被Yeal采纳,获得10
7秒前
ptcl发布了新的文献求助10
7秒前
00发布了新的文献求助10
7秒前
7秒前
8秒前
Grin发布了新的文献求助10
9秒前
awslla发布了新的文献求助10
9秒前
1+1发布了新的文献求助10
10秒前
独特的兔子完成签到,获得积分10
10秒前
嘿嘿完成签到,获得积分20
10秒前
10秒前
Eris发布了新的文献求助10
10秒前
潇洒哥发布了新的文献求助10
11秒前
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8162816
求助须知:如何正确求助?哪些是违规求助? 9557103
关于积分的说明 21738393
捐赠科研通 7753330
什么是DOI,文献DOI怎么找? 3427963
关于科研通互助平台的介绍 2552742
邀请新用户注册赠送积分活动 2472556